Your browser doesn't support javascript.
loading
Widespread and Functional RNA Circularization in Localized Prostate Cancer.
Chen, Sujun; Huang, Vincent; Xu, Xin; Livingstone, Julie; Soares, Fraser; Jeon, Jouhyun; Zeng, Yong; Hua, Junjie Tony; Petricca, Jessica; Guo, Haiyang; Wang, Miranda; Yousif, Fouad; Zhang, Yuzhe; Donmez, Nilgun; Ahmed, Musaddeque; Volik, Stas; Lapuk, Anna; Chua, Melvin L K; Heisler, Lawrence E; Foucal, Adrien; Fox, Natalie S; Fraser, Michael; Bhandari, Vinayak; Shiah, Yu-Jia; Guan, Jiansheng; Li, Jixi; Orain, Michèle; Picard, Valérie; Hovington, Hélène; Bergeron, Alain; Lacombe, Louis; Fradet, Yves; Têtu, Bernard; Liu, Stanley; Feng, Felix; Wu, Xue; Shao, Yang W; Komor, Malgorzata A; Sahinalp, Cenk; Collins, Colin; Hoogstrate, Youri; de Jong, Mark; Fijneman, Remond J A; Fei, Teng; Jenster, Guido; van der Kwast, Theodorus; Bristow, Robert G; Boutros, Paul C; He, Housheng Hansen.
Afiliación
  • Chen S; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Huang V; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Xu X; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.
  • Livingstone J; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Soares F; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.
  • Jeon J; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Zeng Y; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.
  • Hua JT; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.
  • Petricca J; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.
  • Guo H; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.
  • Wang M; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.
  • Yousif F; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Zhang Y; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada; College of Life Sciences, Central China Normal University, Wuhan, Hubei, China; College of Basic Medical Sciences, Dali University, Dali, Yunnan, China.
  • Donmez N; Vancouver Prostate Centre, Vancouver, British Columbia, Canada.
  • Ahmed M; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.
  • Volik S; Vancouver Prostate Centre, Vancouver, British Columbia, Canada.
  • Lapuk A; Vancouver Prostate Centre, Vancouver, British Columbia, Canada.
  • Chua MLK; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Heisler LE; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Foucal A; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Fox NS; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Fraser M; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Bhandari V; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Shiah YJ; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Guan J; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada; College of Electrical Engineering and Automation, Xiamen University of Technology, Xiamen, China.
  • Li J; State Key Laboratory of Genetic Engineering, Department of Neurology, School of Life Sciences and Huashan Hospital, Fudan University, Shanghai, China.
  • Orain M; Research Centre of CHU de Québec-Université Laval, Québec City, Québec, Canada.
  • Picard V; Research Centre of CHU de Québec-Université Laval, Québec City, Québec, Canada.
  • Hovington H; Research Centre of CHU de Québec-Université Laval, Québec City, Québec, Canada.
  • Bergeron A; Research Centre of CHU de Québec-Université Laval, Québec City, Québec, Canada.
  • Lacombe L; Research Centre of CHU de Québec-Université Laval, Québec City, Québec, Canada.
  • Fradet Y; Research Centre of CHU de Québec-Université Laval, Québec City, Québec, Canada.
  • Têtu B; Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
  • Liu S; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada; Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Department of Radiation Oncology, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada.
  • Feng F; Department of Radiation Oncology, University of California, San Francisco, San Francisco, CA, USA; Department of Urology, University of California, San Francisco, San Francisco, CA, USA; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA; Helen Diller Family Comp
  • Wu X; Translational Medicine Research Institute, Geneseeq Technology, Toronto, Ontario, Canada.
  • Shao YW; Translational Medicine Research Institute, Geneseeq Technology, Toronto, Ontario, Canada; School of Public Health, Nanjing Medical University, Nanjing, Jiangsu, China.
  • Komor MA; Translational Gastrointestinal Oncology, Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Oncoproteomics Laboratory, Department of Medical Oncology, VU University Medical Center, Amsterdam, the Netherlands.
  • Sahinalp C; Vancouver Prostate Centre, Vancouver, British Columbia, Canada.
  • Collins C; Vancouver Prostate Centre, Vancouver, British Columbia, Canada; Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
  • Hoogstrate Y; Department of Urology, Erasmus Medical Centre, Rotterdam, the Netherlands.
  • de Jong M; GenomeScan, Leiden, the Netherlands.
  • Fijneman RJA; Translational Gastrointestinal Oncology, Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Fei T; College of Life and Health Sciences, Northeastern University, Shenyang, China.
  • Jenster G; Department of Urology, Erasmus Medical Centre, Rotterdam, the Netherlands.
  • van der Kwast T; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada; Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, Canada.
  • Bristow RG; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada; Division of Cancer Sciences, University of Manchester, Manchester, UK; The Christie NHS Foundation Trust, Manchester, UK; Manchester Cancer Research Centre, Manchester, UK.
  • Boutros PC; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada; Ontario Institute for Cancer Research, Toronto, Ontario, Canada; Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, Canada; Department of Human Genetics, University of California, Lo
  • He HH; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada. Electronic address: Hansenhe@uhnresearch.ca.
Cell ; 176(4): 831-843.e22, 2019 02 07.
Article en En | MEDLINE | ID: mdl-30735634
ABSTRACT
The cancer transcriptome is remarkably complex, including low-abundance transcripts, many not polyadenylated. To fully characterize the transcriptome of localized prostate cancer, we performed ultra-deep total RNA-seq on 144 tumors with rich clinical annotation. This revealed a linear transcriptomic subtype associated with the aggressive intraductal carcinoma sub-histology and a fusion profile that differentiates localized from metastatic disease. Analysis of back-splicing events showed widespread RNA circularization, with the average tumor expressing 7,232 circular RNAs (circRNAs). The degree of circRNA production was correlated to disease progression in multiple patient cohorts. Loss-of-function screening identified 11.3% of highly abundant circRNAs as essential for cell proliferation; for ∼90% of these, their parental linear transcripts were not essential. Individual circRNAs can have distinct functions, with circCSNK1G3 promoting cell growth by interacting with miR-181. These data advocate for adoption of ultra-deep RNA-seq without poly-A selection to interrogate both linear and circular transcriptomes.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / ARN Límite: Humans / Male Idioma: En Revista: Cell Año: 2019 Tipo del documento: Article País de afiliación: Canadá

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / ARN Límite: Humans / Male Idioma: En Revista: Cell Año: 2019 Tipo del documento: Article País de afiliación: Canadá